

# AZURE HEALTH TECHNOLOGY LIMITED

---

23 December 2019

ASX Markets Announcements  
Australian Securities Exchange  
Level 40, Ct Georges Terrace  
Perth WA 6000


## APPOINTMENT OF DIRECTORS

Azure Health Technology Limited (AZT or the Company) is pleased to announce that that Mr Lou Panaccio has been appointed to the board as an independent non executive Chairman and Dr Glenn Tong has been appointed to the board as a non executive director.

These appointments are part of the process towards the acquisition of Invictus Biopharma Ltd (IVB) and the requote of the Company as outlined in the Memorandum of Understanding announced to the market on 8 November 2019. Once the acquisition of IVB is complete, it is proposed that Dr Tong will be appointed as the Chief Executive Officer and Managing Director of the Company.

Mr Panaccio is a successful healthcare businessman with extensive experience progressing companies from concept to commercialisation. Mr Panaccio possesses more than 30 years' executive leadership experience in healthcare services and life sciences, and more than 25 years board-level experience. Mr Panaccio is currently a Non-Executive Director of an ASX50 company and one of the world's largest medical diagnostics companies, Sonic Healthcare Limited, where he has served since 2005. In addition, Mr Panaccio is also a Non-Executive Director of Unison Housing Corporation Limited, Non-Executive Chairman of ASX-listed biotechnology companies Avita Medical Limited (ASX:AVH) and Non-Executive Director of Rhythm Biosciences Limited (ASX:RHY). Mr Panaccio has also served in executive and board roles with Melbourne Pathology Group, Monash IVF Group, Primelife Corporation Limited and other private entities.

Dr Tong has over 20 years of executive management and Board experience in rapid growth biotech companies where a core focus has been the management of product development in highly regulated environments including: pharmaceuticals, diagnostics and genetically modified crops and pastures. Glenn has raised and managed over \$100M in equity capital and collaborative R&D funding. Past roles include: CEO and Managing Director of Gordagen Pharmaceuticals Pty Ltd., the Molecular Plant Breeding Cooperative Research Centre and Molecular Plant Breeding Pty Ltd., and AgGenomics Pty Ltd. (a subsidiary of Genetic Technologies Limited, ASX:GTG). Glenn has a Bachelor of Science (Honours) and PhD (Chemistry) from the University of Melbourne and the Howard Florey Institute of Experimental Physiology and Medicine and is a Graduate and Fellow of the Australian Institute of Company Directors.



Gregory Starr  
**DIRECTOR**